4-(3-氨基苯基)-哌啶-1-羧酸叔丁酯 | 387827-19-2

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 羧酸酯及其衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-(3-氨基苯基)-哌啶-1-羧酸叔丁酯
• 中文别名: 4-(3-氨基-苯基)-哌啶-1-甲酸叔丁基酯；4-(3-氨基-苯基)-哌啶-1-甲酸 叔丁基 酯
• 英文名称: tert-butyl 4-(3-aminophenyl)piperidine-1-carboxylate
• 英文别名: 4-(3-aminophenyl)piperidine-1-carboxylic acid tert-butyl ester；tert-butyl 4-[3-(amino)phenyl]-1-piperidinecarboxylate
• CAS: 387827-19-2
• 化学式: C₁₆H₂₄N₂O₂
• 分子量: 276.379
• InChiKey: INZSWUJHGMIAJM-UHFFFAOYSA-N

物化性质

• 沸点：
  413.2±45.0 °C(Predicted)
• 密度：
  1.100±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  4-(3-氨基苯基)-哌啶-1-羧酸叔丁酯 在 吡啶 、 盐酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 1-ethyl-3-(3-(piperidine-4-yl)phenyl)urea
  参考文献：
  名称：

  [EN] PIPERIDINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN
  [FR] DÉRIVÉS DE PIPÉRIDINE AYANT UNE ACTIVITÉ MULTIMODALE CONTRE LA DOULEUR

  摘要：

  本发明涉及具有对σ受体和μ-阿片受体双重药理活性的化合物，更特别地涉及具有这种药理活性的哌啶化合物，涉及制备这种化合物的方法，包括它们的药物组合物，以及它们在治疗中的使用，特别是用于疼痛治疗。

  公开号：

  WO2015091939A1
• 作为产物：
  描述：

  间溴硝基苯 在 tris-(dibenzylideneacetone)dipalladium(0) 、 palladium 10% on activated carbon 、 氢气 、 sodium carbonate 、 tri tert-butylphosphoniumtetrafluoroborate 作用下， 以 1,4-二氧六环 、 乙醇 、 水 为溶剂， 20.0~90.0 ℃ 、275.8 kPa 条件下， 反应 30.33h， 生成 4-(3-氨基苯基)-哌啶-1-羧酸叔丁酯
  参考文献：
  名称：

  [EN] BRAF DEGRADERS
  [FR] AGENTS DE DÉGRADATION DE BRAF

  摘要：

  本发明提供了能够特异性降解BRAF的化合物。这些化合物可用于治疗各种癌症。

  公开号：

  WO2021255212A1

文献信息

• Substituted alkyl amido piperidines
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US20040186103A1

  公开（公告）日：2004-09-23

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

  这项发明涉及选择性拮抗黑色素浓缩激素-1（MCH1）受体的化合物。该发明提供了一种包括该发明化合物的治疗有效量和药学上可接受的载体的药物组合物。该发明提供了一种由结合本发明化合物的治疗有效量和药学上可接受的载体制成的药物组合物。该发明还提供了一种制备药物组合物的方法，包括结合本发明化合物的治疗有效量和药学上可接受的载体。该发明还提供了一种减少受试者体重的方法，包括向受试者施用本发明化合物的有效量以减少受试者的体重。该发明还提供了一种治疗患有抑郁症和/或焦虑症的受试者的方法，包括向受试者施用本发明化合物的有效量以治疗受试者的抑郁症和/或焦虑症。
• Substituted anilinic piperidines as MCH selective antagonists
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US06727264B1

  公开（公告）日：2004-04-27

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therepeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

  这项发明涉及对黑素集中激素-1（MCH1）受体具有选择性的拮抗剂化合物。发明提供了一种药物组合物，包括治疗有效量的本发明化合物和药用可接受载体。本发明还提供了一种通过结合本发明的治疗有效量的化合物和药用可接受载体来制造的药物组合物。本发明进一步提供了一种制造药物组合物的方法，包括结合治疗有效量的本发明化合物和药用可接受载体。
• 4-Aryl piperidines
  申请人：Marzabadi R. Mohammad

  公开号：US20050154020A1

  公开（公告）日：2005-07-14

  This invention is directed to 4-aryl piperidines and related heterocyclic compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

  本发明涉及4-芳基哌啶及其相关杂环化合物，这些化合物是对黑素集中激素-1（MCH1）受体的选择性拮抗剂。本发明提供了一种药物组合物，包括治疗有效量的本发明化合物和药用可接受的载体。本发明还提供了一种通过结合治疗有效量的本发明化合物和药用可接受的载体而制成的药物组合物。本发明进一步提供了一种制备药物组合物的方法，包括结合治疗有效量的本发明化合物和药用可接受的载体。本发明还提供了一种减少主体体质量的方法，包括向主体施用有效减少主体体质量的本发明化合物的量。本发明还进一步提供了一种治疗患有抑郁和/或焦虑的主体的方法，包括向主体施用有效治疗主体的抑郁和/或焦虑的本发明化合物的量。
• [EN] FAK AND FLT3 INHIBITORS<br/>[FR] INHIBITEURS DE FAK ET FLT3
  申请人：CANCER THERAPEUTICS CRC PTY LTD

  公开号：WO2014027199A1

  公开（公告）日：2014-02-20

  The use of a compound of the formula (I): (Formula (I)) in the preparation of a medicament for treating Acute Myeloid Leukemia or a disease ameliorated by the inhibition of Flt3, or Flt3 and FAK.

  使用公式(I)的化合物：(公式(I))在制备用于治疗急性髓系白血病或通过抑制Flt3、或Flt3和FAK得到改善的疾病的药物中的应用。
• [EN] SECONDARY AMINO ANILINIC PIPERIDINES AS MCH1 ANTAGONISTS AND USES THEREOF<br/>[FR] PIPERIDINES AMINOANILINIQUES SECONDAIRES UTILISEES COMME ANTAGONISTES DE LA MCH1 ET UTILISATIONS CORRESPONDANTES
  申请人：SYNAPTIC PHARMACEUTICAL CORPOR

  公开号：WO2004005257A1

  公开（公告）日：2004-01-15

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compounds of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.

  本发明涉及对黑素集中激素-1（MCH1）受体具有选择性的拮抗剂化合物。该发明提供了一种含有治疗有效量的本发明化合物和药用辅料的药物组合物。本发明还提供了一种通过结合治疗有效量的本发明化合物和药用辅料制成的药物组合物。本发明进一步提供了一种制作含有治疗有效量的本发明化合物和药用辅料的药物组合物的方法。本发明还提供了一种减少主体体质量的方法，包括向主体施用有效减少主体体质量的本发明化合物的量。本发明还提供了一种治疗患有抑郁和/或焦虑的主体方法，包括向主体施用有效治疗主体的抑郁和/或焦虑的本发明化合物的量。本发明还提供了一种治疗患有尿路障碍的主体方法。